Home › Merck challenges Gilead with $3.85B hepatitis C acquisition
 

Keywords :   


Merck challenges Gilead with $3.85B hepatitis C acquisition

2014-06-10 05:02:20| Biotech - Topix.net

Merck will spend about $3.85 billion for Idenix Pharmaceuticals, a small company developing hepatitis C medicines that, together with Merck's experimental drugs, could produce lucrative combo therapies that quickly cure most patients with the blood-borne virus afflicting tens of millions.

Tags: challenges acquisition hepatitis merck

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.10Tropical Storm Milton Public Advisory Number 2
05.10Hurricane Kirk Graphics
05.10Hurricane Kirk Forecast Discussion Number 26
05.10Tropical Storm Milton Graphics
05.10Hurricane Kirk Wind Speed Probabilities Number 26
05.10Hurricane Leslie Graphics
05.10Hurricane Kirk Public Advisory Number 26
05.10Summary for Hurricane Kirk (AT2/AL122024)
More »